Tempus AI shares rose sharply in Wednesday trading, with the move attributed to a reimbursement catalyst: CMS granted Advanced Diagnostic Laboratory Test (ADLT) status for Tempus’ next-generation sequencing assay. The designation improves reimbursement clarity for the test and can increase investor confidence in near-term monetization for high-value clinical diagnostics.

ADLT status is important because it provides a clearer path to Medicare reimbursement for qualifying advanced diagnostics, reducing uncertainty around payment levels and utilization economics. In the read-through for Tempus, the decision supports demand generation and revenue quality for a flagship FDA-approved assay positioned for tumor mutation profiling using matched normal sequence analysis.

Traders will focus on how quickly the reimbursement tailwind translates into higher testing volumes, better gross margins, and any update to guidance cadence. The next key checkpoints are management commentary on payer mix and realized reimbursement rates, plus evidence that improved coverage accelerates adoption among oncologists and health systems.